Squalene causes incurable diseases in animals

Squalene causes incurable diseases in animals
by S. C.
Vaccine additives containing the oil squalene could be toxic, releases its list of 30 peer-reviewed scientific papers showing the debilitating diseases induced in animals immunized with squalene.Withholding this information from volunteers enrolled in clinical trials testing swine flu vaccines containing this oil – and from the general public encouraged to consider vaccination with it should conditions warrant – violates informed consent standards upheld by the Nuremberg Code, the World Medical Assembly’s Declaration of Helsinki and the U.S. Department of Health and Human Services’ Rules and Regulations for the Protection of Human Research Subjects. Squalene is an “adjuvant” – a substance used to accelerate and intensify the immune system’s response to weak vaccines.Officials with the U.S. Department of Health and Human Services (HSS) and U.K. National Health Service (NHS) have argued for the possible inclusion of squalene adjuvants in candidate swine flu vaccines without informing the public that rats injected with squalene develop the animal versions of rheumatoid arthritis and multiple sclerosis; and induces antibodies specific to systemic lupus erythematosus in mice. Rheumatoid arthritis, MS and lupus are incurable autoimmune diseases – diseases that occur when the immune system attacks the body it is supposed to defend. Examination of rats injected with squalene showed severe inflammation in their joints; other show lesions in the brain and nerves stripped of their insulation called the myelin sheath. Demyelization is a clinical hallmark of MS. There are two squalene adjuvants being tested in clinical trials in the U.S. Europe, Asia and South America - MF59 from Novartis and AS03 from GlaxoSmithKline. According to the manufacturers, at least 46 thousand volunteers are now enrolled in clinical trials for swine flu shots containing MF59 and AS03. Novartis and GlaxoSmithKline say their adjuvants are safe. The Novartis adjuvant, MF59, is already licensed in a seasonal influenza approved for human use in the European Union. Around 40 million doses have been distributed in Europe safely, Novartis says.
by S. C. 30 September 2009 TN 8 Year 1